文献速递白血病

仿制三氧化二砷治疗急性早幼粒细胞白血病的资源利用与成本效果

Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide.
PubMed 文献 · Br J Haematol · 2019-12-21

该单中心回顾性研究采用自下而上成本法,比较仿制三氧化二砷方案(APL-ATO)与化疗方案(APL-CT)治疗急性早幼粒细胞白血病的直接医疗成本与健康资源利用,并将成本及生存复发概率代入三状态马尔可夫模型评估成本效果。结果显示APL-ATO治疗成本与资源利用显著低于APL-CT。

要点

  • 仿制ATO方案治疗成本显著低于化疗方案
  • 仿制ATO方案减少住院、抗生素及抗真菌药物使用
  • 马尔可夫模型显示仿制ATO五年治疗成本更低

核心结论

  • 仿制三氧化二砷治疗急性早幼粒细胞白血病的治疗成本和健康资源利用显著低于化疗方案。

研究设计与样本

  • 单中心回顾性研究,采用自下而上成本法比较APL-ATO与APL-CT的直接医疗成本和健康资源利用。
  • 将成本和生存、复发概率代入三状态马尔可夫决策模型估算成本效果。
  • APL-ATO组n=30,APL-CT组n=30。

临床怎么用

  • 在可获得仿制三氧化二砷的地区,可优先考虑其用于APL治疗以降低医疗成本和资源利用。

局限性

  • 研究为单中心回顾性设计,样本量有限(每组n=30)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Arsenic trioxide (ATO)-based regimens are the standard of care for treating acute promyelocytic leukaemia (APL) and have replaced chemotherapy-based approaches. However, the cost of "patented" ATO is prohibitive because of patent rights. "Generic" ATO has been used in a few countries, but its implications for health resource utilization (HRU) and cost of treatment are unknown. We hypothesized that treating APL patients using generic ATO (APL-ATO) will be cost effective compared to the chemotherapy-based regimen (APL-CT). In a single-centre retrospective study, we used a bottom-up costing method to compare the direct medical cost of treatment and HRU between APL-ATO and APL-CT. These costs and the survival and relapse probabilities were imputed in a three-state Markov decision model to estimate the cost effectiveness of APL-ATO compared to APL-CT. The mean cost of treatment for APL-ATO (n = 30, $8500 ± 2078) was significantly less than for APL-CT (n = 30, $22 600 ± 5528) (P < 0·001). APL-ATO reduced hospitalization, antibiotic and antifungal usage (P < 0·001). In the Markov model, five-year treatment costs were significantly lower for APL-ATO ($11 131) than for APL-CT ($17 926) (P < 0·001). Treatment cost and health resource utilization were significantly lower for generic ATO-treated APL patients compared to the chemotherapy-based regimen.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Bankar A, Korula A, Kulkarni UP, et al. Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide. Br J Haematol. 2019. PMID: 31863602. doi:10.1111/bjh.16343

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。